Cost-effectiveness and budget impact of venetoclax in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia in Switzerland

被引：0
|
作者：
Michaela Barbier
Nicholas Durno
Craig Bennison
Mathias Örtli
Christian Knapp
Matthias Schwenkglenks
机构：
[1] University of Basel,Institute of Pharmaceutical Medicine (ECPM)
[2] OPEN Health,undefined
[3] AbbVie AG,undefined
来源：
The European Journal of Health Economics | 2022年 / 23卷
关键词：
Rituximab; Venetoclax; Chronic lymphocytic leukemia; Cost-effectiveness; Partitioned survival model; EVPI; 119;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
下载
收藏
页码：837 / 846
页数：9
相关论文
共 50 条
  • [1] Cost-effectiveness and budget impact of venetoclax in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia in Switzerland
    Barbier, Michaela
    Durno, Nicholas
    Bennison, Craig
    Ortli, Mathias
    Knapp, Christian
    Schwenkglenks, Matthias
    EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2022, 23 (05): : 837 - 846
  • [2] Cost-Effectiveness of Venetoclax and Rituximab Combination Therapy in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) in Argentina
    Elgart, Jorge Federico
    Glancszpigel, Mariana
    Kanevsky, Diego
    Godar, Maria
    Touliet, Valeria
    Albaytero, Natalia
    BLOOD, 2019, 134
  • [3] Cost-effectiveness of a 24-month fixed duration of venetoclax in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia
    Bennison, Craig
    Durno, Nicholas
    Sail, Kavita
    Alexiou, Dimitra
    Mato, Anthony
    Eyre, Toby
    Follows, George
    LEUKEMIA & LYMPHOMA, 2020, 61 : 153 - 155
  • [4] COST-EFFECTIVENESS OF IBRUTINIB AND RITUXIMAB FOR THE RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA IN CHINA
    Yang, F.
    Kumar, A.
    Rojanasarot, S.
    Schommer, J. C.
    Shao, R.
    VALUE IN HEALTH, 2018, 21 : S31 - S31
  • [5] COST-EFFECTIVENESS OF A 24-MONTH FIXED DURATION OF VENETOCLAX IN COMBINATION WITH RITUXIMAB IN RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA IN THE UNITED STATES
    Huntington, S. F.
    Strunz-McKendry, T.
    Masaquel, A. S.
    Shapouri, S.
    Sail, K.
    Durno, N.
    Mato, A.
    VALUE IN HEALTH, 2019, 22 : S78 - S79
  • [6] COST-EFFECTIVENESS OF VENETOCLAX AND RITUXIMAB COMBINATION THERAPY VERSUS IBRUTINIB IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (R/R CLL) IN COLOMBIA
    Chacon-Acevedo, K. R.
    Gamboa, O.
    Quitian Reyes, D.
    VALUE IN HEALTH, 2020, 23 : S37 - S37
  • [7] COST-EFFECTIVENESS OF IDELALISIB IN COMBINATION WITH RITUXIMAB FOR THE TREATMENT OF RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) IN PORTUGAL
    Gouveia, M.
    Silva, M. G.
    Alarcao, J.
    Fiorentino, F.
    Carda, J.
    Costa, R.
    Mariz, J. M.
    Raposo, J.
    Costa, J.
    Borges, M.
    VALUE IN HEALTH, 2015, 18 (07) : A461 - A462
  • [8] COST-EFFECTIVENESS OF IDELALISIB IN COMBINATION WITH RITUXIMAB FOR THE TREATMENT OF RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) IN PORTUGAL
    Silva, M. G.
    Gouveia, M.
    Alarcao, J.
    Fiorentino, F.
    Carda, J.
    Costa, R. M.
    Mariz, J. M.
    Raposo, J.
    Borges, M.
    HAEMATOLOGICA, 2015, 100 : 577 - 577
  • [9] COST-EFFECTIVENESS OF VENETOCLAX IN COMBINATION WITH RITUXIMAB IN RELAPSED/ REFRACTORY CHRONICLYMPHOCYTIC LEUKEMIA IN FOUR GULF COUNTRIES
    Hamad, A.
    Abdaljalil, A.
    Abdellatif, H. Y.
    Aladarbeh, Q. T.
    Al Farsi, K.
    Alhuraiji, A.
    Gamaleldin, A. M.
    Hamadah, A.
    Ismail, H. A.
    Osman, H. Y.
    Siddiqui, M.
    Taha, R. Y.
    Tannira, M.
    Pandita, R.
    VALUE IN HEALTH, 2023, 26 (06) : S67 - S68
  • [10] Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
    Seymour, J. F.
    Kipps, T. J.
    Eichhorst, B.
    Hillmen, P.
    D'Rozario, J.
    Assouline, S.
    Owen, C.
    Gerecitano, J.
    Robak, T.
    De la Serna, J.
    Jaeger, U.
    Cartron, G.
    Montillo, M.
    Humerickhouse, R.
    Punnoose, E. A.
    Li, Y.
    Boyer, M.
    Humphrey, K.
    Mobasher, M.
    Kater, A. P.
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (12): : 1107 - 1120
12345